Kyowa Kirin Co., Ltd. (FRA:KY4)

Market Cap	6.86B
Revenue (ttm)	2.91B
Net Income (ttm)	226.71M
Shares Out	n/a
EPS (ttm)	0.43
PE Ratio	30.27
Forward PE	n/a
Dividend	0.35 (2.76%)
Ex-Dividend Date	Jun 27, 2025

Volume	n/a
Average Volume	19
Open	12.90
Previous Close	12.80
Day's Range	12.90 - 12.90
52-Week Range	12.30 - 15.50
Beta	n/a
RSI	41.73
Earnings Date	Oct 30, 2025

About Kyowa Kirin

Kyowa Kirin Co., Ltd. engages in the research, development, manufacture, import/export, and market of pharmaceuticals products worldwide. The company offers Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; POTELIGEO for the treatment of cutaneous T-cell lymphoma; Nouriast/Nourianz, an adenosine A2A receptor antagonist; G-LASTA, a mobilization of hematopoietic stem cells into peripheral blood for autologous blood stem cell transplantation; Libmeldy/Lenmeldy for treating metachro...

• Industry: Pharmaceutical Preparations
• Founded: 1949
• Employees: 5,669
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: KY4

Financial Performance

In 2024, Kyowa Kirin's revenue was 495.56 billion, an increase of 12.06% compared to the previous year's 442.23 billion. Earnings were 59.87 billion, a decrease of -26.26%.

Financial numbers in JPY